Portal de Periódicos da CAPES

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease

2017; Elsevier BV; Volume: 1; Issue: 20 Linguagem: Inglês

10.1182/bloodadvances.2017009613

2473-9537

Joshua J. Field, Elaine M. Majerus, Victor R. Gordeuk, Michel Gowhari, Carolyn Hoppe, Matthew M. Heeney, Maureen Achebe, Alex George, Hillary C. Chu, Brian J. Sheehan, Mäneka Puligandla, Donna Neuberg, Gene Lin, Joel Linden, David G. Nathan,

Erythrocyte Function and Pathophysiology

Key Points Regadenoson did not reduce iNKT cell activation to a prespecified level when administered to patients with SCD. Because iNKT cell activation was not reduced, the benefit of iNKT cell-based therapies in SCD cannot be determined.